B-
BiotechTV - News
Abingdon, UK based T-Cypher Bio believes that the future of T-cell engagers will focus on intracellular targets - preclinical data on two novel targets, TC25 & TC11, will be at SITC
0:00-11:20
CEO Sarah Leonard describes the company's focus and process. The lead program, TC25, is scheduled to be in the clinic in 2028, and the company also has plans to go after auto-immune conditions in addition to oncology.
Publisher
BiotechTV - News
Link
podcasters.spotify.com/pod/show/biotechtv4/episodes/Abingdon--UK-based-T-Cypher-Bio-believes-that-the-future-of-T-cell-engagers-will-focus-on-intracellular-targets---preclinical-data-on-two-novel-targets--TC25--TC11--will-be-at-SITC-e3rlucn
Published
November 3, 2026
Duration
11 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BiotechTV
B-
BiotechTV - News
@biotechtvnews
#cypherbiobelieves #intracellulartargets #preclinicaldata #lifesciences
